Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance ...

Tumor growth and metastasis require new blood ves-sel growth, a process called angiogenesis. There are many factors involved in the nor-mal growth and stabilization of new blood vessels. One of these, ...

While studying the formation of the kidney, researchers realized that a gene they had deleted to examine the effect of its absence on kidney function also had negative impacts elsewhere in the body: ...

CHESTERBROOK, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...

MELBOURNE, Australia & SAN DIEGO--(BUSINESS WIRE)--Akaal Pharma, a clinical-stage drug discovery and development company, today announced the publication of preclinical studies of safety and efficacy ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.

Targeting sphingosine-1-phosphate receptors with the oral immunomodulator drug FTY720 (fingolimod) has demonstrated substantial efficacy in the treatment of multiple sclerosis. The drug is ...

T regulatory cells, or Treg cells, are a subtype of CD4+ cells. They are responsible for inducing self-tolerance by a host of immune suppressive actions mediated by various immune cells, especially ...

Autobahn Therapeutics Inc. has disclosed fatty acid amide (FAAH) cleavable prodrugs acting as sphingosine 1-phosphate S1P1 receptor (S1PR1; EDG1) and/or S1P5 receptor (S1PR5; EDG8) agonists reported ...

While Ventyx Biosciences Inc.’s oral S1P1 receptor modulator, VTX-002, achieved primary and secondary endpoints in a phase II ulcerative colitis (UC) trial, the company’s shares (NASDAQ:VTYX) fell ...

Taicang, Suzhou, July 30, 2015 – Suzhou Connect Biopharma announced today that it has successfully completed the single ascending dose study of its lead clinical candidate CBP-307 in healthy ...